Open company graph database — free web & API
Login

Transgenic Group Inc.

株式会社トランスジェニックグループTRANSGENIC GROUP INC.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
227
Related companies
25
§01

Basic information

BASIC
Head office
2-3-36 Tenjin, Chuo-ku, Fukuoka City
Chief executive
Kenji Fukunaga
Capital
50,000,000
Employees (non-consolidated)
6 people
Employees (consolidated)
227 people
Start date
1998-04-21
End date
§02

Websites

1 DOMAINS
§03

Business

5
Drug discovery support businessInvestment and consulting businessFormulating and promoting group-wide management strategies as a holding company, and management controlDevelopment, manufacturing, and sales of antibodiesGene knockout mouse business
§04

Related companies

25 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Primeun Corporation
Group Customer
Medifom Co., Ltd.
Group Customer
Rupex Japan Inc.
Group Customer
Limited Liability Partners General Audit Corporation
Group
Anpyo Center Co., Ltd.
Group
Shinyaku Research Center Co., Ltd.
Group
Gyarakusu Trading Co., Ltd.
Group Customer
MASC Corporation
Group Customer
Kumamoto Antibody Research Institute Inc.
Group
Tohoku Shinwa Chemical Co., Ltd.
Group Customer
LunaPath Toxicology and Pathology Research Institute
Group Customer
Primmune Therapeutics
Group
TGM Corporation
Group
Hope Corporation
Group Customer
Outlet Plaza Co., Ltd.
Group Customer
Akihabara Outlet Plaza
Group
Medicinal Chemistry Pharmaceutical, Co.,Ltd.(MCP)
Group Customer
TGM Corporation
Group Customer
Tomei Trading Co., Ltd.
Group Customer
TG Business Service Co., Ltd.
Group Customer
TG Business Service Co., Ltd.
Group
Lupex Japan Inc.
Group
Mediffom Inc.
Group
Genetic Lab Inc.
Group
Transgenic Group Inc.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

101 EVENTS

Founded KUMAMOTO Antibody Research Institute Inc. in Egoshi, Kumamoto City, with capital of 11 million yen, for the development, manufacturing, and sale of antibody reagents for protein function analysis.Sources

On April 21, 1998, established Kumamoto Antibody Laboratory Inc. with capital of 11 million yen in Egoshi, Kumamoto City, for the purpose of developing, manufacturing, and selling antibodies as reagents for protein function analysis.Sources

Established: April 21, 1998.Sources

Established: April 21, 1998.Sources

In April 2000, opened Tokyo Sales Office (Tokyo Office). Relocated headquarters to Kuhonji, Kumamoto City. Transferred the rights to the “Gene Trap Method Using Trap Vectors” from the Kumamoto Techno Poliss Foundation (now Public Interest Incorporated Foundation Kumamoto Industry Support Foundation), and started the gene knockout mouse business, changing the company name to Transgenic Inc.Sources

Opened Tokyo Sales Office (Tokyo Office). Moved headquarters to Kyuhoji, Kumamoto City.Sources

Opened Tokyo Sales Office (Tokyo Office).Sources

Relocated headquarters to Kuhonji, Kumamoto City.Sources

Received transfer of 'Gene Trap Vector and Gene Trap Method Using It' from Kumamoto Techno Poliss Foundation (now Public Interest Incorporated Foundation Kumamoto Industry Support Foundation), and started gene knockout mouse business, changing the trade name to Transgenic Corporation.Sources

In August 2000, relocated headquarters to Chuo Street, Kumamoto City.Sources

Moved headquarters to Chuo Street, Kumamoto City.Sources

Relocated headquarters to Chuo Street, Kumamoto City.Sources

In December 2001, signed a sales agreement for gene knockout mouse sequence information with Yakult Honsha Co., Ltd. (now Astellas Pharma Inc.) and Sumitomo Chemical Co., Ltd.Sources

Entered into a sales agreement for gene knockout mouse sequence information with Yamauchi Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.).Sources

Entered into a sales agreement for gene knockout mouse sequence information with Sumitomo Chemical Co., Ltd. (now Sumitomo Chemical Co., Ltd.).Sources

Entered into a sales agreement for gene knockout mouse sequence information with Yamanochi Pharmaceutical Co., Ltd. (now Astellas Pharma Inc.).Sources

Entered into a sales agreement for gene knockout mouse sequence information with Sumitomo Chemical Co., Ltd. (now Sumitomo Chemical Co., Ltd.).Sources

In December 2002, listed on the Mothers Market of the Tokyo Stock Exchange.Sources

Listed on the Tokyo Stock Exchange Mothers Market.Sources

Listed on Tokyo Stock Exchange Mothers Market.Sources

In June 2003, relocated headquarters to Masaki Town, Kamimashiki District, Kumamoto Prefecture.Sources

Moved headquarters to Mashiki Town, Kamimashiki District, Kumamoto Prefecture.Sources

Relocated headquarters to Masaki Town, Kamimashiki District, Kumamoto Prefecture.Sources

In July 2005, established Kobe Research Institute.Sources

Established the Kobe Research Institute.Sources

Established Kobe Research Institute.Sources

In February 2006, relocated headquarters to Minami Kumamoto, Kumamoto City.Sources

Relocated headquarters to Minami Kumamoto, Kumamoto City.Sources

Relocated headquarters to Minami Kumamoto, Kumamoto City.Sources

In May 2006, acquired shares of Primeum Corporation (now a consolidated subsidiary) and made it a subsidiary.Sources

Acquired shares to make Primeum Corporation (now a consolidated subsidiary) a subsidiary.Sources

Made PrimeUnion Co., Ltd. (now a consolidated subsidiary) a subsidiary through share acquisition.Sources

In December 2012, relocated headquarters to Chuo Ward, Kumamoto City.Sources

Relocated headquarters to Chuo Ward, Kumamoto City.Sources

Relocated headquarters to Chuo Ward, Kumamoto City.Sources

In April 2013, established Shinyaku Research Center Inc. (now a consolidated subsidiary). Transferred business from Shinyaku Development Laboratory to Shinyaku Research Center Inc.Sources

Established New Drug Research Center Corporation (now a consolidated subsidiary). Transferred business from New Drug Development Laboratory Corporation.Sources

Established Shin-Yaku Research Center Co., Ltd. (now a consolidated subsidiary).Sources

Transferred business from Shin-Yaku Development Research Institute to Shin-Yaku Research Center Co., Ltd.Sources

In July 2013, acquired shares of Medifom Inc. (now a consolidated subsidiary) and made it a subsidiary. Made Genetic Lab Inc. (now a consolidated subsidiary) a subsidiary through third-party allotment of shares.Sources

Acquired shares to make Medifom Corporation (now a consolidated subsidiary) a subsidiary.Sources

Made Genetic Lab Corporation (now a consolidated subsidiary) a subsidiary through third-party allotment of new shares.Sources

Acquired shares of Medifom Inc. (currently a consolidated subsidiary) to make it a subsidiary.Sources

Made Genetic Laboratory Inc. (currently a consolidated subsidiary) a subsidiary through third-party allotment of new shares.Sources

In July 2015, made Medical Chemistry Drug Discovery Inc. (now a consolidated subsidiary) a related company through third-party allotment of shares. Moved headquarters to Chuo Ward, Fukuoka City.Sources

Made Pharmaceutical Chemistry Drug Discovery Corporation (now a consolidated subsidiary) a related company through third-party allotment of new shares.Sources

Relocated headquarters to Chuo Ward, Fukuoka City.Sources

Made Medical Chemistry Drug Discovery Inc. (currently a consolidated subsidiary) an affiliated company through third-party allotment of new shares.Sources

Relocated headquarters to Chuo Ward, Fukuoka City.Sources

In November 2017, established TG Business Service Inc. (now a consolidated subsidiary). Acquired shares of Lopexx Japan Inc. (now a consolidated subsidiary) and made it a subsidiary.Sources

Established TG Business Service Corporation (now a consolidated subsidiary).Sources

Acquired shares to make Loupex Japan Corporation (now a consolidated subsidiary) a subsidiary.Sources

Established TG Business Service Inc. (currently a consolidated subsidiary).Sources

Made Lupex Japan Inc. (currently a consolidated subsidiary) a subsidiary through share acquisition.Sources

In February 2018, acquired shares of Outlet Plaza Inc. (now a consolidated subsidiary) and made it a subsidiary.Sources

Acquired shares to make Outlet Plaza Corporation (now a consolidated subsidiary) a subsidiary.Sources

Made Outlet Plaza Inc. (currently a consolidated subsidiary) a subsidiary through share acquisition.Sources

March 2018: Established Anpo Center Inc. (now a consolidated subsidiary).Sources

Established Yasuhyo Center Corporation.Sources

Established Yasuhyo Center Inc. (currently a consolidated subsidiary).Sources

April 2018: Acquired business from Food, Agriculture, Medical and Pharmaceutical Safety Evaluation Center, a public interest incorporated foundation, at Anpo Center Inc.Sources

Transferred business from the Food, Agriculture, Medical and Pharmaceutical Safety Evaluation Center, a public interest incorporated foundation, to Yasuhyo Center Corporation.Sources

Transferred business from the Food, Agriculture, Medical, and Pharmaceutical Safety Evaluation Center, a public interest incorporated foundation, to Yasuhyo Center Inc.Sources

April 2019: Made TGM Inc. (now a consolidated subsidiary) a subsidiary through share acquisition.Sources

Acquired shares to make TGM Corporation (now a consolidated subsidiary) a subsidiary.Sources

Made TGM Inc. (currently a consolidated subsidiary) a subsidiary through share acquisition.Sources

March 2020: Made Galax Trade Inc. (now a consolidated subsidiary) a subsidiary through share acquisition.Sources

Acquired shares to make Galax Trade Corporation (now a consolidated subsidiary) a subsidiary.Sources

Made Garlax Trading Inc. (currently a consolidated subsidiary) a subsidiary through share acquisition.Sources

April 2021: Transitioned to a pure holding company structure.Sources

Transitioned to a pure holding company structure.Sources

Transitioned to a pure holding company structure.Sources

Explanation materials regarding business plan and growth potentialSources

January 2022: Transferred all shares of Genetick Lab Inc. to Eurofins Clinical Testing Japan Holding Inc.Sources

Transferred all shares of Genetic Lab Corporation to Eurofins Clinical Testing Japan Holding Corporation.Sources

Transferred all shares of Genetic Laboratory Inc. to Eurofins Clinical Testing Japan Holding Inc.Sources

April 2022: Changed from the Mothers Market to the Growth Market on the Tokyo Stock Exchange following a review of market classification.Sources

Due to the review of market classification by the Tokyo Stock Exchange, transitioned from the Mothers Market to the Growth Market.Sources

Changed from the Tokyo Stock Exchange Mothers Market to the Growth Market due to a review of market classification.Sources

Explanation materials regarding business plan and growth potentialSources

September 2022: Made Tomei Shokai Inc. (now a consolidated subsidiary) a subsidiary through share acquisition.Sources

Acquired shares to make Tōmei Shōkai Corporation (now a consolidated subsidiary) a subsidiary.Sources

Made Tomen Trading Inc. (currently a consolidated subsidiary) a subsidiary through share acquisition.Sources

January 2023: Excluded from subsidiaries following the transfer of all shares of Kizuki Inc.Sources

Transferred all shares of Kizuki Corporation, excluding it from the subsidiary.Sources

Excluded from subsidiaries by transferring all shares of Kizuki Inc.Sources

March 2023: Made MASC Inc. (now a consolidated subsidiary) a subsidiary through share acquisition.Sources

Made MAS Corporation (now a consolidated subsidiary) a subsidiary through share acquisition.Sources

Made MASC Inc. (currently a consolidated subsidiary) a subsidiary through share acquisition.Sources

Explanation materials regarding business plan and growth potentialSources

June 2024: Made Tohoku Shinkwa Chemical Inc. a subsidiary through share acquisition.Sources

Made Tohoku Shinkwa Chemical Corporation a subsidiary through share acquisition.Sources

Made Tohoku Shinwa Chemical Inc. a subsidiary through share acquisition.Sources

Explanation materials regarding business plan and growth potentialSources

October 2024: Merged New Drug Research Center Inc. and Anpo Center Inc. through absorption-type merger with New Drug Research Center Inc. as the surviving company, and changed the trade name to Transgenic Inc., then to Transgenic Group Inc.Sources

Merged with Shin-Yaku Research Center Co., Ltd. and Shin-Yaku Center Co., Ltd. using an absorption-type merger with Shin-Yaku Research Center Co., Ltd. as the surviving company, and changed the trade name to Transgenic Corporation. Changed the trade name to Transgenic Group Corporation.Sources

Merged Shinyaku Research Center Inc. and Yasuhyo Center Inc. by absorption-type merger with Shinyaku Research Center Inc. as the surviving company, and changed the trade name to Transgenic Inc.Sources

Changed the trade name to Transgenic Group Inc.Sources

Matters regarding business plan and growth potentialSources

Changed market to Tokyo Stock Exchange Standard Market.Sources

Changed market to the Tokyo Stock Exchange Standard Market.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information9330001006698
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社トランスジェニックグループ
Trade name (kana)
トランスジェニックグループ
Name in English
Corporation type
301
Address
〒810-0001 福岡県福岡市中央区天神2丁目3番36号
Postal code
8100001
Prefecture code
40
City code
133
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2024-10-15
Change date
2024-10-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
11
Correction type
0
Trade name image ID
Address image ID
Sequence number
5373720
METI gBizINFO9330001006698
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
9330001006698
Trade name
株式会社トランスジェニックグループ
Trade name (kana)
トランスジェニックグループ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
福岡県福岡市中央区天神2丁目3番36号
Postal code
8100001
Prefecture
福岡県
Prefecture code
40
City or district
福岡市中央区
City code
133
Street address
天神2丁目3番36号
Organisation type
301
Processing type
11
Correction type
0
Status
Representative
代表取締役社長  福永 健司
Capital
50000000
Employees
6
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2024-10-15
Key information
9330001006698
§09

Sources & updates

SOURCES
↑